• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Encysive Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds for the treatment of a variety of cardiovascular, vascular and related inflammatory diseases. Co.'s research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. Co. has developed one Food and Drug Administration approved drug, Argatroban, for the treatment of heparin-induced thrombocytopenia (HIT) that is marketed by GlaxoSmithKline.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2008-06-10 | 0 | |
|
DIXON RICHARD A F SR. V.P. RESEARCH & CSO |
|
No longer subject to file | 2008-06-10 | 0 |
|
No longer subject to file | 2008-06-10 | 0 | |
|
69,076,466 | 2008-04-11 | 0 | |
|
0 | 2008-04-03 | 0 | |
|
0 | 2008-04-03 | 0 | |
|
0 | 2008-04-03 | 0 | |
|
0 | 2008-04-03 | 0 | |
|
PIETRUSKI JOHN M |
|
0 | 2008-04-01 | 0 |
|
0 | 2008-04-01 | 0 | |
|
0 | 2008-04-01 | 0 | |
|
0 | 2008-04-01 | 0 | |
|
0 | 2008-04-01 | 0 | |
|
MAETZOLD DEREK J V.P., MARKETING & SALES |
|
0 | 2008-04-01 | 0 |
|
DILLON JOHN H II |
|
0 | 2008-04-01 | 0 |
|
MANIERRE PAUL S V.P. AND GENERAL COUNSEL |
|
0 | 2008-04-01 | 0 |
|
COLE GEORGE W PRESIDENT AND CEO |
|
0 | 2008-04-01 | 0 |
|
KEYSER D JEFFREY V.P., REGULATORY AFFAIRS |
|
0 | 2008-04-01 | 0 |
|
GOEGGEL RICHARD A V.P., FINANCE & CORP TREASURER |
|
0 | 2008-04-01 | 0 |
|
GIVEN BRUCE D PRESIDENT & CEO |
|
345,523 | 2007-03-14 | 0 |
|
BUSENBARK GORDON H CHIEF FINANCIAL OFFICER |
|
103,501 | 2007-03-14 | 0 |
|
CARLUCCI FRANK C |
|
78,790 | 2006-07-10 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
